ESPE Abstracts

Aim: To assess the efficacy of faster aspart (FIAsp) in paediatric population with type 1 diabetes mellitus (T1DM) and insulin pumps in real-world settings.

Methods: We conducted a prospective analysis of 16 children and adolescents with T1DM on insulin pump that switched from Aspart to FIAsp from September 2019 to June 2020. We performed within groups and between groups analyses in three time points: 3 months before FIAsp, 3 months after FIAsp and recent data of FIAsp. Data that were collected included: % of 24-h time in range of 70-180 mg/dl (TIR), time in hypoglycaemia (<70 mg/dl and <54 mg/dl) and hyperglycaemia (>180 mg/dl and >250 mg/dl), bolus and basal insulins doses (units/kg/day and %), total daily dose (units/kg/day), glycaemic variability, frequency of set changes and meals per day.

Results: Although data from the first trimester of FIAsp use did not show any statistical improvements, recent data showed significantly increased TIR (58.68 % vs 68.75%, P= 0.002) and decreased time in hyperglycaemia (>180 mg/dl, 27.31% vs 22%, P= 0.003 and >250 mg/d, 12.25% vs 6.75%, P= 0.004). The use of FIAsp, both 3 months after the switch and recent use, increased total daily dose (0.65 vs 0.72 units/kg/day, P= 0.008 and 0.65 vs 0.82 units/kg/day, P= 0.004, respectively). Surprisingly enough, frequency of set changes was significantly reduced in FIAsp in the first 3 months of use (1 every 2.36 days vs 1 every 2.66 day, P= 0.042).

Conclusion: Real-world data confirm that the use of FIAsp in children wearing pumps is associated with improvements in glycemic control. These results are more prominent in recent real-world data as during the 1st trimester of use patients/caregivers were limited by a strict protocol.